ABSTRACT
OBJECTIVE: To explore the prognostic factors of young and middle-aged patients with acute myeloid leukemia (AML) and the predictive value of minimal residual disease (MRD) before consolidation therapy. METHODS: The clinical data of 262 middle-risk young and middle-aged patients with AML treated in our hospital from January 2010 to December 2018 were selected retrospectively. All the patients were reached morphological leukemia-free state (MLFS) after induction chemotherapy, the overall and subgroup clinical data of the selected patients were analyzed. Cox regression model was used to evaluate the independent prognostic factors of middle-risk newly diagnosed young and middle-aged patients. RESULTS: Among the patients less than 40 years old treated by consolidation therapy with PR-CT and allo-HSCT regimens, the 5-year cumulative leukemia-free survival(LFS) rates were 40.92% and 63.51%ï¼P=0.01ï¼respectively, while those over 40 years old were 23.61% and 49.14%ï¼P=0.00ï¼, respectively. The 5-year cumulative LFS rates of the patients treated by chemotherapy and achieved early remission and late remission were 63.51% and 41.33% ï¼P=0.01ï¼, respectively. The 5-year cumulative overall survival(OS) rates of the patients treated by PR-CT and allo-HSCT regimens were 23.65% and 69.32% (P=0.00), respectively, and the 5-year cumulative LFS rates were 26.44% and 52.30% (P=0.01). Among the patients treated by PR-CT consolidation treatment, the MRD-negative and MRD-positive cases were 74 and 60 cases, respectively. The 5-year cumulative incidence of relapse rate in the MRD-negative subgroup was significantly lower than those in the MRD-positive subgroup (P<0.05), the 5-year LFS rate and OS rate of the patients in MRD-negative subgroup were significantly higher than those in MRD-positive subgroup (P<0.05). For the patients treated by allo-HSCT consolidation treatment, the MRD-negative and MRD-positive cases were 66 and 62 cases, respectively. The 5-year cumulative incidence of relapse rate of the patients in MRD-negative subgroup was significantly lower than those in MRD-positive subgroupï¼P<0.05ï¼, and the 5-year LFS and OS rates of the patients in MRD-negative subgroup were significantly higher than those in MRD-positive subgroup (P<0.05). The univariate analysis results showed that age, chromosome karyotype, MRD status after reaching MLFS, and consolidation treatment regime were all related to the prognosis of patients (P<0.05). The multivariate analysis results showed that age, MRD status after reaching MLFS, and consolidation therapy were the independent factors affecting the cumulative OS rate of the patients (P<0.05). Chromosome karyotype was an independent factor affecting the cumulative LFS rate of the patients (P<0.05). MRD status and consolidation treatment plan after reaching MLFS were the independent factors affecting the cumulative recurrence rate of the patients (P<0.05). CONCLUSION: The OS rate of middle-risk young and middle-aged patients with newly diagnosed AML is independently related to age, MRD status after MLFS and consolidation therapy, while chromosome karyotype is independently related to cumulative LFS, and allo-HSCT consolidation therapy is recommended for middle-risk young and middle-aged AML patients after induction chemotherapy for MLFS, especially for those less than 40 years old and MRD positive before consolidation therapy.
Subject(s)
Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute , Adult , Consolidation Chemotherapy , Humans , Middle Aged , Neoplasm, Residual , Prognosis , Retrospective StudiesABSTRACT
Boron nitride (BN) was used as a support and covered with an ionic liquid (IL) and tungsten disulfide (WS2) nanoparticles to obtain an electrode for the determination of 4-aminophenol (4-AP). BN was prepared using a "solvent cutting" method, and the BN-IL-WS2 nanocomposite was obtained by an ultrasonic method. BN and its hybrids were characterized by scanning electron microscopy, transmission electron microscopy and X-ray diffraction. When the BN-IL-WS2 composites were coated on the surface of the electrode, the response to 4-AP was strongly amplified due to the strong synergetic effect between the three materials. The voltammetric response of the modified sensor (with a maximum at 0.29 V vs. Ag/AgCl) in solutions with a pH of 6 is linear in the 0.01-50 µΜ 4-AP concentration range, and the limit of detection is 3 nM. A modified glassy carbon electrode was applied for the determination of 4-AP in seawater and dispersions containing paracetamol tablets. The results were consistent with those obtained by HPLC. Graphical abstract Schematic representation of the voltammetric determination process of 4-aminophenol (4-AP). The electrochemical sensor based on the glassy carbon electrode modified with boron nitride (BN), ionic liquid (IL) and tungsten disulfide (WS2) nanomaterials. They, exhibit an excellent performance compared with other electrodes.
ABSTRACT
Molybdenum disulfide (MoS2) was used as an electrically conductive skeleton and functionalized with an ionic liquid and gold/silver nanorods. The resulting composite was characterized by scanning electron microscopy, transmission electron microscopy and UV-vis spectroscopy. The composites were used to modify a glassy carbon electrode (GCE) to obtain a sensor for 2,4-dichlorophenol (2,4-DCP). The results show that the oxidation power and electrocatalytic activity of the modified GCE towards 2,4-DCP are enhanced compared to a bare GCE and other modified GCEs. Response is linear in the 0.01 to 50 µM 2,4-DCP concentration range, with a 2.6 nM detection limit. The sensor is highly sensitive and long-term stable. It was successfully applied to the determination of 2,4-DCP in spiked water samples and gave satisfactory recoveries. Graphical abstract Schematic of an electrochemical sensor for the differential pulse voltammetric (DPV) determination of 2,4-dichlorophenol. It is based on the use of an MoS2-ionic liquid-Au/Ag nanorod composite.
